AKT1 and lung cancer: It has recently been demonstrated that administering tyrosine kinase inhibitors (TKIs) to block PI3K/Akt signaling can significantly reduce the amount of GLUT1 that is bound to the cell membrane, despite increasing the synthesis of TXNIP in lung cancer tissues [70].